Article

A one-in-a-billion chance at success

Author(s):

What if you could count tiny bits of tumor in the bloodstream to predict whether a drug is working against cancer, rather than measuring the tumor itself? That's what researchers are doing in a formal collaboration with the Food and Drug Administration as part of an effort to make clinical trials faster, more efficient and less expensive.The research team, led by Howard Scher, MD, of Memorial Sloan-Kettering Cancer Center in New York, investigated whether tests that trap circulating tumor cells, or CTCs, could determine whether patients with advanced prostate cancer responded to Zytiga (abiraterone), a drug that targets a protein in the production of testosterone, which stimulates cancer cell growth. CTCs represent about one cell in a billion in the blood stream, Scher says.In the study of 1,195 patients, the median overall survival rate improved by 4.6 months. The researchers tested the blood of 972 patients at the beginning of the trial, and 723 patients after three months, finding that Zytiga reduced the number of CTCs and extended patients' lives.Prostate cancer is common in older men, and the standard screening test for prostate-specific antigen, or PSA, is unreliable because it sometimes rises even when a patient is benefiting from treatment, Scher says. But measuring CTCs predict a better prognosis and overall survival as early as four weeks after treatment.The researchers are continuing their work to define biological signals known as biomarkers that can predict which patients are the best match for drugs or give an early indication that treatments are working.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
2 experts are featured in this series.
Illustration of doctor.
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of man.
Image of Crispino
Image of Dr. Reznick
Related Content